Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model

Journal of Experimental and Clinical Cancer Research

Volumn 27, Issue 1, 2008, Pages

  Chade, Daher C ^a   Borra, Ricardo C ^b   Nascimento, Ivan P ^c   Villanova, Fabiola E ^a   Leite, Luciana C C ^c   Andrade, Enrico ^a   Srougi, Miguel ^a   Ramos, Kátia L ^a   Andrade, Priscila M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b IBIRAPUERA UNIVERSITY   (Brazil)

^c INSTITUTO BUTANTAN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; INTERLEUKIN 10; MESSENGER RNA; PERTUSSIS TOXIN; PERTUSSIS TOXIN SUBUNIT 1; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CANCER VACCINE; IMMUNOLOGIC FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER; BLADDER CANCER; BLADDER TUMOR; C57BL 6 MOUSE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER TRANSPLANTATION; CAUTERIZATION; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG INSTILLATION; FEMALE; IMMUNOMODULATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR CELL; TUMOR VOLUME; WEIGHT REDUCTION; WILD TYPE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DISEASE MODEL; GENETICS; IMMUNOLOGY; MYCOBACTERIUM BOVIS; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; BCG VACCINE; CANCER VACCINES; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; PERTUSSIS TOXIN; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 62149100674     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-27-78     Document Type: Article

References (17)

1. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. LJ Old DA Clarke B Benacerraf, Nature 1959 184 Suppl 5 291 292 10.1038/184291a0 14428599
2. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. A Morales D Eidinger AW Bruce, The Journal of urology 1976 116 180 183 820877
3. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. HW Herr A Morales, The Journal of urology 2008 179 53 56 10.1016/j.juro.2007.08.122 17997439
4. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. RJ Sylvester AP van der Meijden JA Witjes K Kurth, The Journal of urology 2005 174 86 91 discussion 91-82. 10.1097/01.ju.0000162059.64886.1c 15947584
5. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG). V Pansadoro P Emiliozzi F depaula, J Exp Clin Cancer Res 2003 22 223 227 16767936
6. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. HW Herr G Dalbagni, The Journal of urology 2003 169 1706 1708 10.1097/01.ju.0000062605.92268.c6 12686813
7. Complications of intravesical therapy for urothelial cancer of the bladder. MP Koya MA Simon MS Soloway, The Journal of urology 2006 175 2004 2010 10.1016/S0022-5347(06)00264-3 16697786
8. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. A Agarwal S Verma U Burra, Cancer Immunol Immunother 2006 55 734 743 10.1007/s00262-005-0045-2 16283306
9. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity. R Nadler Y Luo W Zhao, Clin Exp Immunol 2003 131 206 216 12562379 10.1046/j.1365-2249.2003.02071.x
10. Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice. IP Nascimento WO Dias RP Mazzantini, Infect Immun 2000 68 4877 4883 10948100 10.1128/IAI.68.9.4877-4883.2000
11. Optimizing syngeneic orthotopic murine bladder cancer (MB49). JH Gunther A Jurczok T Wulf, Cancer Res 1999 59 2834 2837 10383142
12. Histopathological characterization of a syngeneic orthotopic murine bladder cancer model. DC Chade PM Andrade RC Borra, Int Braz J Urol 2008 34 220 229 10.1590/S1677-55382008000200013 18462521
13. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. KJ Livak TD Schmittgen, Methods (San Diego, Calif) 2001 25 402 408 11846609
14. Role of animal models in understanding intravesical therapy with bacille Calmette-Guerin. TL Ratliff, Clin Infect Dis 2000 31 Suppl 3 S106 108 10.1086/314065 11010834
15. Cutting edge: immune cells as sources and targets of the IL-10 family members? K Wolk S Kunz K Asadullah R Sabat, J Immunol 2002 168 5397 5402 12023331
16. Interleukin-10 therapy - review of a new approach. K Asadullah W Sterry HD Volk, Pharmacological reviews 2003 55 241 269 10.1124/pr.55.2.4 12773629
17. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. J Riemensberger A Bohle S Brandau, Clin Exp Immunol 2002 127 20 26 11882028 10.1046/j.1365-2249. 2002.01734.x